Abstract 2086P
Background
Management of opioids use disorder in cancer survivors The morbidity and mortality associated with opioid use disorder is a public health concern in many countries. However, opioids are a cornerstone in the management of cancer pain. The problem of opioid use disorders is an emerging concern in cancer survivors.
Methods
Over 10 months, we evaluated at the Gustave Roussy Pain Management Unit survivors of cancer who were on long-term prescription opioid therapy. A thorough evaluation involving an addiction specialist doctor, a psychologist or a psychiatrist, and the pain team was conducted to answer the following questions: - What is the current painful complaint and are opioids the adequate treatment for it? - Is the patient dependent on prescription opioids and does he/she have prescription opioid misuse? - Does the patient have an addiction to opioids (according to DSMV criteria) A personalized therapeutic project was then proposed for each patient.
Results
All patients accepted the project. Thirteen patients with a prescription opioid use disorder were enrolled for an opioid withdrawal program. Nine patients were misusing step-3 analgesics as defined by the WHO analgesic ladder, including one patient misusing fast-acting fentanyl, and 4 were misusing step-2 analgesics as monotherapy or in combination with another step-2 analgesic. The mean oral morphine equivalent doses were 150 mg daily [40-480 mg]. Nine patients had an opioid prescription renewal for more than 5 years. The fear of the pain rebound was the main obstacle to stopping opioid use. Seven patients could be withdrawn as outpatients six required hospitalizations for withdrawal under strict medical supervision. Five patients were put on Medications for Opioid Use Disorder (MOUD). None of the residual pain complaints warranted an opioid prescription.
Conclusions
Prescription opioids use disorder in cancer survivors requires the intervention of a specialized multidisciplinary team, trained in the identification and treatment of opioid withdrawal, in the handling of MOUD and in the management of chronic pain diseases. Close and regular collaboration with oncologists is necessary, to reconsider the need for prescription opioids in every patient as soon as he/she is in remission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy Cancer Campus Grand Paris.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06